2025
Cost-effective pricing of long-acting injectable HIV pre-exposure prophylaxis for adolescent girls and young women in South Africa: a model-based analysis
Jin E, Ahmed A, Bekker L, Rousseau E, Dugdale C, Flanagan C, Wallace M, Freedberg K, Orrell C, Reddy K, Paltiel A, Ciaranello A, Neilan A. Cost-effective pricing of long-acting injectable HIV pre-exposure prophylaxis for adolescent girls and young women in South Africa: a model-based analysis. The Lancet Global Health 2025, 13: e1230-e1239. PMID: 40441175, PMCID: PMC12223965, DOI: 10.1016/s2214-109x(25)00119-6.Peer-Reviewed Original ResearchConceptsHIV pre-exposure prophylaxisPre-exposure prophylaxisLife yearsIncremental cost-effectiveness ratioTDF-FTCCAB-LAAdolescent girlsYoung womenHIV-related careHealth-care sector perspectiveDaily oral tenofovir disoproxil fumarateIncrease life-yearsDaily oral TDF-FTCOral tenofovir disoproxil fumaratePrEP programmesCumulative HIV-transmissionHIV incidencePrEP persistenceTenofovir disoproxil fumarateCost-effectiveness ratioHIV transmissionCost-effectiveModel-projected outcomesSouth AfricaPrEP drugs
2018
The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India
Zheng A, Kumarasamy N, Huang M, Paltiel AD, Mayer KH, Rewari BB, Walensky RP, Freedberg KA. The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India. Journal Of The International AIDS Society 2018, 21: e25085. PMID: 29603882, PMCID: PMC5878415, DOI: 10.1002/jia2.25085.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careAntiretroviral therapyTenofovir disoproxil fumarateHIV infectionRecent guidelinesFirst-line antiretroviral therapyFirst-line HIV treatmentLifetime incremental cost-effectiveness ratioART-naive patientsDolutegravir-based regimenDTG-based regimenFirst-line treatmentClinical trial dataCost-effectiveness ratioLifetime care costsInitial therapyVirologic suppressionCD4 countHIV diseaseRegimen costsDisoproxil fumarateHIV treatmentAIDS complicationsCare costs
2015
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States
Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clinical Infectious Diseases 2015, 62: 784-791. PMID: 26658053, PMCID: PMC4772845, DOI: 10.1093/cid/civ981.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careVirologic suppressionART costsBudget impactHuman immunodeficiency virus (HIV) treatmentART-naive patientsDTG/ABC/3TCVirologic suppression ratesSubsequent virologic failureCost-effectiveness ratioPerson/yearInitial regimenAntiretroviral therapyInduction regimenNaive patientsVirologic failureAntiretroviral agentsDual therapyHIV infectionTwo-drugDolutegravirVirus treatmentRegimenSurvival rate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply